Treating Bipolar Depression With Atypical Antipsychotics: Pros, Cons, and Tips

Slideshow

Depression predominates across the lifespan in patients with bipolar disorder. Here: A discussion about (and beyond) the four FDA-approved drugs to treat symptoms.

Related Videos
brain depression
brain
Related Content
Here are highlights from the week in Psychiatric Times.

The Week in Review: April 15-19

April 20th 2024
Article
Blue Light Blockers: A Behavior Therapy for Mania

Blue Light Blockers: A Behavior Therapy for Mania

October 7th 2021
Podcast
depression

New Phase 3 Study Results on Lumateperone, An Adjunctive Therapy to Antidepressants

April 16th 2024
Article
Blue Light, Depression, and Bipolar Disorder

Blue Light, Depression, and Bipolar Disorder

August 4th 2021
Podcast
From a groundbreaking FDA approval to the hidden toll of COVID-19, here are highlights from the week in Psychiatric Times.

The Week in Review: April 1-5

April 6th 2024
Article
“The selectivity of NBI-1070770 for the NMDA NR2B receptor may benefit patients with moderate to severe depression.”

First Patient Dosed in Phase 2 Clinical Trial of NBI-1070770 for MDD

April 3rd 2024
Article
© 2024 MJH Life Sciences

All rights reserved.